Table 1.
Clinical Characteristics of Subjects and Cerebrospinal Fluid Parameters
| Subject number | Cluster, Fig 1 | Sex, M/F | Age, active | Subarachnoid cyst location | Paired/unpaired | Active time point LP | Cure time point LP | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total anthelmintics previously, months | Time to cure, months | Steroid dose, prednisone equivalent | Other immuno-modulator | CSF WBC, cells/mm3 | CSF glucose, mg/dL | CSF TsAg, ng/mL | CSF qPCR, Dq value | Steroid dose, prednisone equivalent | Other immuno-modulator | CSF WBC, cells/mm3 | CSF glucose, mg/dL | CSF TsAg, ng/mL | CSF qPCR, Cq value | Follow-up, years | ||||||
| 1 | C | F | 41 | Spine | Paired | 0 | 16.8 | 35 | None | 30 | 47 | 4000 | 30.0 | 8.75 | Etanercept, anakinra | 18 | 54 | 0 | No amplification | 1 |
| 2 | B | M | 39 | Basilar cistern | Paired | 6 | 50.8 | 40 | None | 174 | 89 | 751 | 20.1 | 0 | None | 10 | 116 | 0 | No amplification | 4 |
| 3 | C | M | 51 | Basilar cistern, sylvian fissurea | Paired | .25 | 9.3 | 53.3 | None | 16 | 54 | 529 | 29.6 | 0 | Methotrexate | 2 | 53 | 0 | No amplification | 5.3 |
| 4 | B | F | 41 | Basilar cistern, sylvian fissure | Paired | 0 | 47.1 | 53.3 | None | 15 | 48 | 2624 | 27.4 | 0 | None | 5 | 53 | 0 | No amplification | 2.5 |
| 5 | B | M | 31 | Basilar cistern, sylvian fissureb | Paired | 4 | 21.7 | 0 | Methotrexate | 135 | 28 | 101 | 26.6 | 0 | None | 9 | 52 | 1.5c | 35.5 | 1.6 |
| 6 | B | M | 36 | Spine | Paired | 5 | 13.2 | 0 | Methotrexate | 51 | 43 | 440 | 30.4 | 0 | Etanercept | 3 | 37 | 0 | 36.0 | 8.3 |
| 7 | B | M | 41 | Sylvian fissure, basilar cistern | Paired | 4 | 12.2 | 7.5 | None | 7 | 52 | 11 | 30.3 | 0 | None | 45 | 50 | 0 | 35.2 | 2.7 |
| 8 | A | M | 51 | Spine, basilar cistern | Paired | 15 | 18.4 | 0 | None | 34 | 43 | 157 | 26.8 | 0 | Methotrexate | 3 | 62 | 0 | 36.0 | 8.3 |
| 9 | A | M | 57 | Sylvian fissure, spine | Paired | 14 | 13.7 | 53.3 | None | 3 | 29 | 119 | 29.5 | 10 | Methotrexate, etanercept | 5 | 55 | 0 | No amplification | 5 |
| 10 | B | F | 28 | Spine | Unpaired | 13 | 4.7 | 0 | None | 12 | 44 | 578 | 36.9 | … | … | … | … | … | … | … |
| 11 | C | M | 33 | Basilar cistern, sylvian fissurea | Unpaired | .25 | 6.4 | 0 | None | 44 | 36 | 871 | 28.8 | … | … | … | … | … | … | … |
| 12 | C | M | 37 | Basilar cistern, sylvian fissureb | Unpaired | 2 | 15.1 | 106.7 | None | 7 | 95 | 147 | 26.5 | … | … | … | … | … | … | … |
| 13 | B | F | 42 | Basilar cistern, spinea,b | Unpaired | 1 | 23.0 | 133.3 | Methotrexate | 23 | 0 | 139 | 27.0 | … | … | … | … | … | … | … |
| 14 | C | F | 44 | Basilar cisternb | Unpaired | 2 | 79.0 | 10 | Methotrexate | 153 | 60 | 7600 | 23.1 | … | … | … | … | … | … | … |
| 15 | B | M | 40 | Basilar cistern, sylvian fissure, spine | Unpaired | 11 | 115.5 | 0 | Methotrexate | 55 | 38 | 20000 | 23.5 | … | … | … | … | … | … | … |
| 16 | C | M | 26 | Sylvian fissurea,b | Unpaired | 0 | 6.3 | 0 | None | 4 | 55 | 38 | No amplification | … | … | … | … | … | … | … |
| 17 | … | M | … | Basilar cistern | Unpaired | … | … | … | … | … | … | … | … | 0 | None | 6 | 63 | 0 | No amplification | 3 |
| 18 | … | F | … | Basilar cistern | Unpaired | … | … | … | … | … | … | … | … | 5 | None | 27 | 41 | 5.4c | 33.2 | 3.4 |
Abbreviations: CSF, cerebrospinal fluid; F, female; LP, lumbar puncture; M, male; qPCR, quantitative polymerase chain reaction; TsAg, Taenia solium antigen; WBC, white blood cell.
aAlso had ventricular disease.
bAlso had calcified parenchymal disease.
cTsAg negative at next LP without the use of anthelmintics.